maintenance – PressAP

JCN Newswire

MHIEC Builds a New Waste-to-Energy Plant with 194 Tons Per Day-Capacity in Konan City, Aichi Prefecture, Japan

February 14, 2023

TOKYO, Feb 14, 2023 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), a Group company of Mitsubishi Heavy Industries, Ltd. (MHI), has received an order from the Owarihokubu Waste Disposal Association for building, operation, and maintenance of a new waste-to-energy plant. The association was established to consolidate waste treatment services of four municipalities in the northern Aichi region: Inuyama City, Konan City, Oguchi Town, and Fuso Town in Niwa County. The order calls for construction of an integrated waste-to-energy plant equipped with two stoker-type incinerators(1) collectively capable of processing 194 tons per day (tpd) in Konan City, to replace two superannuated plants in the association's service area. The operation startup is scheduled for April 2028.New Waste-to-Energy Plant of the Owarihokubu Waste Disposal Association (Rendering)Consolidating the services of four municipalities, the new plant will replace two superannuated facilities: Inuyama Waste Disposal Center (capacity: 135 tpd; designed and built by MHI; located in Inuyama City and operated since 1983) and Konan-Niwa Waste Disposal Center (capacity: 150 tpd; located in Oguchi Town in Niwa County and operated since 1982). Under the DB+O(2) contract, MHIEC will also take charge of providing long-term operation and maintenance services of the new plant for a period of 20 years. The contract is valued at 33.15 billion yen (tax excluded).The new facility will employ state-of-the-art technology for municipal waste processing. Besides two stoker-type incinerators each having a processing capacity of 97 tpd, the plant contributes to lighter environmental footprint by reducing CO2 emissions and providing highly efficient power generation. In addition, under the DBM(3) contract, MHIEC will also take charge of providing long-term maintenance services of a materials recovery facility (capacity: 14 tons/5 hours) that crushes and processes incombustibles. MHIEC aims to create a facility that contributes to the reduction of greenhouse gases through the recovery and effective use of energy, the realization of carbon neutrality and a decarbonized society by 2050, along with the formation of a recycling-oriented society.Bidding for the new plant construction project adopted a comprehensive evaluation method taking into consideration not only the bid price but also factors such as technological strengths and operating expertise. MHIEC was awarded the contract due to its attractive business plan for managing the progress of the construction process under the unified responsibility of MHIEC and specific proposals regarding the operation at the materials recovery facility, in addition to its contributions to the local economy, such as local procurement of construction materials and employment plans for local human resources. In construction and operation of the new facility, MHIEC will work closely with a group of five local companies in the association's service area.MHIEC succeeded MHI's environmental protection business in 2008, taking over its accumulated technological development capabilities in environmental protection systems and abundant expertise in the construction, operation, and maintenance of waste management facilities both in Japan and overseas. Based on this robust track record, the company is well positioned to propose comprehensive solutions encompassing all aspects from plant construction to operation and maintenance, and it can also respond to needs for after-sales servicing and long-term operation and maintenance. Going forward, MHIEC will continue to seek order expansion worldwide through proactive offering of proposals for enhancing the efficiency of existing facilities, making incinerators more advanced through AI and IoT supported remote monitoring and automated operation, and lowering life-cycle costs (LCC).(1) A stoker incinerator is the most widely adopted type of furnace used in waste-to-energy plants. Waste is combusted as it moves along a fire grate made of heat-resistant castings.(2) Under a DB+O (design, build plus operate) contract, a public institution designs, constructs, and owns a facility and comprehensively entrusts the maintenance and management of the facility to a private company for several years.(3) Under a DBM (design, build, maintenance) contract, a public institution designs, constructs, owns, and operates a facility and entrusts the maintenance and management of the facility to a private company. Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

InvesTech Holdings Launches Virsical MetaFM, an Integrated Operations and Management Solution for Corporate Equipment and Facilities

November 11, 2022

HONG KONG, Nov 11, 2022 - (ACN Newswire via SEAPRWire.com) - InvesTech Holdings Limited ("InvesTech Holdings"; together with its subsidiaries, "the Group"; stock code: 1087.HK), a leading integrated smart-IT solutions provider in China, is pleased to announce that Wafer Systems Limited ("Wafer Systems"), a subsidiary of the Group that owns the flagship smart-office software product Virsical, recently launched Virsical MetaFM ("MetaFM"), an integrated operations and management solution for corporate equipment and facilities in commercial real estates and smart buildings. MetaFM outperforms traditional management models and empowers the digital transformation of building operations, maintenance and management.Developed by Wafer Systems, MetaFM is a smart operations management system which is based on the operation, maintenance and management of equipment and facilities in buildings. With input from business interactions and feedback from clients, Wafer Systems has carried out an iterative programme of upgrades to the system. Serving operational goals in areas including security, environmental cleaning and customer service, the system helps optimise the operation, maintenance and management of facilities throughout the full life cycle of buildings. MetaFM offers comprehensive functions, including modules to handle assets and equipment, service centres, order management, preventive maintenance and management, patrol management, inventory management, supplier management, contract management, energy and data management, safe production and emergency planning. As a newly launched smart facility management platform, MetaFM has appealing characteristics, namely comprehensive functional modules, flexible applications, well-established templates, user-friendly interfaces, and a well-designed overall structure, optimising facility management practices. As a solution specifically designed for the operations and maintenance of buildings and properties, MetaFM adopts Wafer Systems' original platform structure while permitting development in new directions for building space management. Leveraging its powerful back-end self-configuration function, the system helps building operators to make accurate decisions on project operations, maintenance and management. The system also significantly reduces facility operations and maintenance costs, lowers potential risks relating to equipment operations, increases transparency in facility management, and maximises the efficiency of facility operations and maintenance. MetaFM can be applied in a diverse range of scenarios, providing a comprehensive smart space management solution for commercial properties, campuses and corporate offices. MetaSpace, as a platform empowered by spatial digital twins, mainly facilitates information technology/operational technology (IT/OT) integration. MetaWork, an application platform specifically designed for enterprise digital administrative tasks, mainly supports enterprise employees and visitors, and serves administrative management functions. MetaView, a platform that features visualisation and analysis tools for enterprise digital data, serves as an enterprise management control panel and interactive screen. MetaSpace, MetaWork and MetaView complement one another in terms of functionality, forming a complete loop to provide high-quality, one-stop services for enterprises.Mr. Ringo Chan, Chairman of InvesTech Holdings, said: "Equipment and facilities play a notably important role in enterprises' production processes and business operations, making the management of equipment and facilities one of the most important aspects of enterprise management. With immense experience in the smart-office sector and experience of serving numerous Fortune 500 clients, we notice that companies are faced with problems in such areas as asset management, operating costs and procedure management. We therefore hope that our newly launched MetaFM can help enterprises overcome different challenges in the operation, maintenance and management of equipment and facilities. Leveraging the most advanced solutions, we have set a new industry standard for facility management, providing more customers with convenient smart-office space and improving overall operations management standards and work efficiency.""The Group has successfully launched the Meta series of smart-building management solutions, which can be deployed in a wide range of scenarios, providing powerful, comprehensive solutions that support enterprises in fields including employee health, user experience, collaborative efficiency, low-carbon and energy-saving operations, corporate sustainability, and environmental, social and governance (ESG) practices. Further, the Group has developed close strategic partnerships with ecosystem partners in the industry, which are leading cloud service and network providers such as Microsoft, Lark, Huawei and Cisco. Looking ahead, leveraging our strong product ecosystem alongside our research and development capabilities, we will continue to develop and optimise solutions to offer our customers one-stop smart-space solutions and facilitate enterprises' digital transformation," Mr. Chan said. About InvesTech Holdings LimitedInvesTech Holdings Limited (stock code: 1087.HK) was listed on the main board of the Hong Kong Stock Exchange in 2010. As a leading integrated smart IT solutions provider with more than 30 years of experience in the IT industry, the Group is engaged principally in IT infrastructure systems integration and the smart-office software solutions businesses. The Group has a strong presence in China, with more than 10 offices nationwide and a research and development centre in Xi'an.Website: http://www.investech-holdings.com/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

IVD Medical Announces 2022 Interim Results

August 22, 2022

HONG KONG, Aug 22, 2022 - (ACN Newswire via SEAPRWire.com) - IVD Medical Holding Limited ("IVD Medical" or the "Group"), a leading distributor of In Vitro Diagnostic ("IVD(1)") products in the PRC, has announced its interim results for the six months ended 30 June 2022 ("Period"). During the Period, although hospitals were closed and other quarantine and social distancing measures were put in place in mainland China due to the COVID-19 pandemic, which resulted in a temporary decrease in end customers' demand for IVD product. With the help of its competitive and diverse product portfolio, extensive distribution network and growing maintenance services business, the Group still recorded revenue of RMB1,176,557,000 (six months ended 30 June 2021: RMB1,186,791,000), a similar level to that in the same period last year. Gross profit increased by 11% year-on-year to RMB266,423,000 and gross profit margin was up 2.4 percentage points year-on-year to 22.6%. The increases were mainly attributable to the decrease in purchase price of IVD analysers and the increase in maintenance services revenue with relatively stable maintenance cost. Driven by rising profit margin, the Group's adjusted profit for the period amounted to RMB96,773,000, 6.7% more year-on-year. The Board resolved to declare the payment of an interim dividend of HK2.729 cents per share for the six months ended 30 June 2022. Mr. Ho Kuk Sing, Chairman of IVD Medical, said, "In 2022, although the business environment of the medical industry has been tough under the pandemic, we have worked hard to overcome challenges and optimize our business operations. For distribution business, we signed a five-year exclusive distribution agreement with Sysmex in April this year. We have expanded our distribution network and hospital coverage to consolidate our position in the industry. Furthermore, our maintenance services business has been developing steadily with the notable growth in revenue, gross profit and gross profit margin. Looking ahead, we are prepared to capture potential growth opportunities in the industry and committed to bring better and long-term returns to shareholders."Business ReviewThe Group is a leading distributor of IVD products in the People's Republic of China ("PRC"). It has also engaged in research, development, manufacturing and sales of its self-branded IVD products.Distribution BusinessThe distribution of IVD products forms the cornerstone of the Group's business. It primarily involves the trading of IVD analysers, reagents and other consumables to customers such as distributors, hospitals and healthcare institutions and logistics providers. During the Period, revenue from this segment was RMB1,097,468,000, with gross profit up 3.1% to RMB216,907,000.Through years of operation, the Group has established an expansive distribution network across 29 provinces, municipalities and autonomous regions in the PRC with an extensive hospital coverage. As of 30 June 2022, the Group has 204 direct customers, including hospitals and healthcare institutions, and 908 distributors in its established distribution network. The Group distributes IVD products through its wholly-owned subsidiary Vastec Medical Limited ("Vastec"). Vastec has been the sole nationwide distributor of Sysmex haemostasis products with exclusive distribution rights in the PRC since 1997, and also procures a diversified portfolio of IVD products from other leading international brands for distribution in the PRC. On 1 April 2022, Vastec signed a five-year distribution agreement of Sysmex haemostasis products with exclusive distribution rights which is valid till 31 March 2027. The agreement has helped to strengthen the long-term and quality cooperation between Vastec and Sysmex. Moreover, the Group has provided four Thrombotic Markers(2) products manufactured by Sysmex to the market. These products adopt highly sensitive chemiluminescence technology, which may facilitate early diagnosis of thrombosis and fibrinolysis. The Group also provides solution services to clinical laboratories of hospitals, as such, it has enabled the Group to establish and maintain direct relationships with local medical practitioners so as to keep the Group close to the frontline of the medical practice and the demand of IVD products. In the first half of 2022, the Group provided solution services to eight Class III hospitals in the PRC.Maintenance ServicesThe Group provides maintenance services to end customers of Sysmex' haemostasis analysers. In 2017, Vastec entered into a maintenance services agreement with Sysmex to provide maintenance services to haemostasis analysers procured by its end customers. The maintenance services provided by Vastec generally include maintenance and repair services, installation services and end customer trainings. And, it primarily provides its maintenance services to hospitals and healthcare institutions. During the Reporting Period, the maintenance services business has been sustainably and steadily developing, with revenue amounted to RMB77,286,000, up by 27.8% against the same period last year. Gross profit of this segment increased by 70.2% to RMB48,388,000 and gross profit margin was up 15.6 percentage points to 62.6% for the period. Self-Branded Products BusinessThe Group has also engaged in the research and development, manufacturing and sales of IVD analysers and reagents under its own brand. The Group's self-branded IVD reagents were manufactured by Suzhou DiagVita Biotechnology Co., Ltd. and Bazoe Medical Co., Ltd., and the Group's IVD analysers were produced by its equipment manufacturers, IVD Medical Equipment (Shanghai) Ltd. and Langmai Biotechnology (Shandong) Co., Ltd. In addition, the Group distributes self-developed IVD products under its own brand which includes IVD analysers and reagents primarily under the IVD testing category of Point-of-care testing ("POCT"), mass spectrometry and microbiology.OutlookIn the future, the Group will continue to consolidate its leading position in the IVD industry in the PRC. To realise this goal, the Group aims to continuously expand its product portfolio by diversifying product categories, increasing brand coverage, and further expanding the breadth of its distribution network and hospital coverage. In this way, the Group will be able to capitalise on the high growth potential in the IVD market.Furthermore, the Group will continue to develop its distribution business by enhancing its capacity in providing solution services. By being the general supplier of the clinical laboratory department in such hospitals, the Group participates in the design of laboratory layout, provides centralised procurement of IVD products, conducts real-time inventory monitoring and provides other after-sale services to clinical laboratories. It also plans to hire more sales personnel to promote and market its solution services and to stock sufficient IVD products of various brands to strengthen its advantages in centralized procurement. To enhance brand awareness, it will continuously participate in national and local IVD symposiums, as well as academic conferences. In addition, the Group believes that strong research and development ("R&D") capabilities are critical to securing its future development and sustainable growth. It will therefore invest more resources to further improve its R&D capabilities by acquiring equipment, instruments and hiring experts in the relevant fields. The Group will also engage in research projects to further develop self-branded IVD products that holding promising market potential. The Group is keen to further strengthen product quality management and optimize the performance and applicability of self-developed products to improve market competitiveness.Mr. Leung King Sun, Chief Operation Officer of the Group, said, "Given the growing medical expenses per capita and government support to the industry pursuing technological development, the Group remains optimistic about the development prospects of the medical market in the PRC, particularly the medical equipment market. Priding competitiveness, a diverse product portfolio, an expansive distribution network and extensive hospital coverage, we are confident of seizing every potential opportunity. Meanwhile, we will continue to strengthen solution services for hospitals and enhance R&D capabilities for our own brands, and ultimately consolidate our leading position in the industry."About IVD Medical Holding LimitedIVD Medical Holding Limited ("IVD Medical" or the "Group") is a leading distributor of IVD products in the PRC. Its key subsidiaries include Vastec Medical Limited, Dacheng Medical Equipments (Shanghai) Co., Ltd., IVD China Limited, Suzhou DiagVita Biotechnology Co., Ltd., Langmai Biotechnology (Shandong) Co., Ltd and Bazoe Medical Co., Ltd. The Group's distribution network covers 29 provinces, municipalities and autonomous regions across the PRC. It is the sole national distributor of Sysmex' haemostasis products in the PRC and provides maintenance services to its end customers. It also engages in the R&D, manufacturing and sales of self-branded IVD analysers and reagents and provides solution services to clinical laboratories of hospitals for centralised procurement.Notes:(1) IVD, "In Vitro Diagnostic", which encompasses tests done on samples such as blood or tissue taken from the human body(2) 4 Thrombotic Markers refer to: 1)TAT: Thrombin-antithrombin complex, 2)PIC: Plasmin - a2-plasmin inhibitor complex, 3)TM: Thrombomodulin, 4)t-PAI-C: Tissue plasminogen activator/plasminogen activator inhibitor-1 complex.Media Enquiries:Strategic Financial Relations LimitedHeidi So Tel: (852) 2114 4320 Email: heidi.so@sprg.com.hkYan Li Tel: (852) 2864 4826 Email: yan.li@sprg.com.hkCherry Chen Tel: (852) 2114 4309 Email: cherry.chen@sprg.com.hkFax: (852) 2527 1196 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)